Semaglutide dosage for weight loss in people without diabetes

You've been told the doses go up gradually, here's why that matters

A lot of people starting semaglutide for weight loss expect the first pen to feel like the real thing. It usually doesn't, and that's by design. The 0.25 mg weekly starting dose isn't a therapeutic level; it exists to let your body adjust to the medicine's effect on your stomach and gut before any meaningful appetite suppression kicks in. Most GI side effects (nausea in particular) are at their worst when the dose changes, not when it settles.

The standard titration moves in roughly four-week steps: 0.25 mg, then 0.5 mg, then 1.0 mg, then 1.7 mg, then 2.4 mg as the maintenance dose. Your prescriber controls that progression; self-advancing is not recommended. The full Wegovy dosage schedule covers what typically happens at each level, including when a pause in titration might be clinically sensible.

The MHRA approved a 7.2 mg maintenance dose for Wegovy in January 2026, with a dedicated single-dose pen following in April 2026. Trial data for the higher dose showed around 20.7% average weight loss over 72 weeks, approaching the results seen with tirzepatide at its highest dose. Eligibility for 7.2 mg is currently restricted to adults with a BMI of 30 or above; the cardiovascular indication uses a different pathway. If you're curious whether the higher dose applies to your situation, that's exactly the kind of question a prescriber can answer during a free consultation.

What changes (and what doesn't) when you don't have diabetes

The honest answer is: less than most people assume. The licensed dose schedule for Wegovy is the same whether or not someone has type 2 diabetes. The difference lies in the product itself. Ozempic (also semaglutide) is licensed for blood sugar management in type 2 diabetes, at doses up to 1.0 mg weekly. It is not licensed for weight management, and prescribing it off-label for that purpose in someone without diabetes is not standard clinical practice in the UK. Semaglutide dosing in type 2 diabetes follows a different ceiling and purpose.

Wegovy is the weight-loss licence. It was evaluated in the STEP 1 trial, which enrolled adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes, and found an average weight reduction of around 15% over 68 weeks at the 2.4 mg dose, compared with placebo, alongside lifestyle changes. More detail on the evidence behind each dose level is available if you want to read further before a consultation.

One practical point our prescribers raise often: the 14 mg tablet you may have read about online is Rybelsus, which is oral semaglutide for type 2 diabetes, not weight loss. The semaglutide 14 mg page explains the distinction clearly. For weight management, the licensed oral option as of June 2026 is the Wegovy tablet, which follows a completely different dose ladder: 1.5 mg, 4 mg, 9 mg and 25 mg.

Side effects to know about, and when to get medical help

The side-effect profile of semaglutide is largely gastrointestinal. Nausea is the most frequently reported symptom and is most likely after starting treatment or moving up a dose level; for most people it settles within a week or two once the body adjusts. Constipation, diarrhoea, indigestion, reflux and fatigue are also commonly reported. None of this is unique to people without diabetes, the pattern is consistent across the trial populations.

Pancreatitis is a rarer but serious risk. In January 2026 the MHRA published a Drug Safety Update specifically highlighting acute pancreatitis across GLP-1 medicines, including semaglutide. If you develop severe stomach pain that spreads toward your back, with or without vomiting, stop the injection and seek urgent medical attention. Don't wait to see if it passes. You can report suspected side effects at the MHRA's Yellow Card scheme.

Keeping your pen in the fridge door (where you'll see it weekly) helps with routine, but it also matters clinically: semaglutide requires refrigeration, and the room-temperature window before it degrades is limited. The Patient Information Leaflet included with your pen gives the exact timing; always check there rather than relying on a general figure. The Wegovy overview covers storage and other practical questions in more depth.

Who can be prescribed semaglutide for weight loss, and who shouldn't be

The licensed threshold for Wegovy is a BMI of 30 or above, or 27 to 29.9 alongside at least one weight-related condition, such as high blood pressure, high cholesterol, type 2 diabetes, or obstructive sleep apnoea. Not having diabetes is not a barrier; it is, in fact, the population the weight-management licence was mainly studied in. Lower BMI thresholds apply for some ethnic backgrounds under UK clinical guidance, reflecting differences in health risk at a given BMI. Our clinical team can clarify how this applies during a review.

There are situations where semaglutide for weight loss is clearly not appropriate. Pregnancy is one: it is not recommended, and the MHRA advises using effective contraception during treatment. If you are planning to conceive, speak to your prescriber about the timing of any wash-out period before you stop contraception. The same applies while breastfeeding. Treatment is also not licensed for anyone under 18. A personal or close family history of medullary thyroid carcinoma or MEN2 syndrome requires discussion before any GLP-1 medicine is considered.

For context on what the NHS covers and what that means for a private route, the Wegovy cost page sets out current pricing honestly alongside what any legitimate provider should include. A broader overview of weight-loss treatment options is also there if you're still weighing things up.